Volume | 647,690 |
|
|||||
News | (1) | ||||||
Day High | 13.63 | Low High |
|||||
Day Low | 12.94 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Verve Therapeutics Inc | VERV | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
13.28 | 12.94 | 13.63 | 13.28 | 13.19 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
9,846 | 647,690 | $ 13.35 | $ 8,646,381 | - | 8.22 - 21.4199 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:23:21 | 75 | $ 13.28 | USD |
Verve Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.11B | 83.62M | - | 11.76M | -200.07M | -2.39 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Verve Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VERV Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 13.61 | 14.2614 | 12.65 | 13.07 | 659,142 | -0.06 | -0.44% |
1 Month | 18.96 | 19.34 | 12.65 | 14.46 | 1,164,277 | -5.41 | -28.53% |
3 Months | 13.05 | 19.34 | 10.3103 | 13.58 | 1,085,399 | 0.50 | 3.83% |
6 Months | 12.58 | 20.12 | 8.22 | 12.68 | 1,390,717 | 0.97 | 7.71% |
1 Year | 14.59 | 21.4199 | 8.22 | 13.81 | 1,023,845 | -1.04 | -7.13% |
3 Years | 30.00 | 78.00 | 8.22 | 22.69 | 842,380 | -16.45 | -54.83% |
5 Years | 30.00 | 78.00 | 8.22 | 22.69 | 842,380 | -16.45 | -54.83% |
Verve Therapeutics Description
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States. |